SCHEMBL31574199

CSCC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)C

nearest known ligand 0.65

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	PTH1R	Q03431	10/20	0.65

▸	IL23R	Q5VWK5	7/20	0.62

▸	KEAP1	Q14145	1/20	0.60

▸	RXFP1	Q9HBX9	1/20	0.59

▸	GLP1R	P43220	1/20	0.57

▸	GCGR	P47871	1/20	0.57

▸	GIPR	P48546	1/20	0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30299196	0.95	PTH1R (0.67)	PTH1RIL23RKEAP1RXFP1GLP1R
SCHEMBL16358962	0.93	PTH1R (0.65)	PTH1RIL23RKEAP1RXFP1
SCHEMBL31232534	0.93	PTH1R (0.68)	PTH1RIL23RKEAP1RXFP1GLP1R
SCHEMBL16358977	0.92	PTH1R (0.63)	PTH1RIL23RKEAP1RXFP1
SCHEMBL29557329	0.91	PTH1R (0.72)	PTH1RIL23RKEAP1RXFP1GLP1R
SCHEMBL31694512	0.91	PTH1R (0.71)	PTH1RIL23RKEAP1RXFP1GLP1R
SCHEMBL13881424	0.90	IL23R (0.57)	PTH1RIL23RKEAP1GLP1RGCGR
SCHEMBL29350300	0.90	PTH1R (0.64)	PTH1RIL23RKEAP1RXFP1GLP1R
SCHEMBL29429587	0.90	PTH1R (0.64)	PTH1RIL23RKEAP1RXFP1GLP1R
Penetratin SCHEMBL29356568	0.90	PTH1R (0.66)	PTH1RIL23RKEAP1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12295916-B2	Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness	DRESDNER JR KARL P (US)	2025-05-13	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12295916-B2	Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness	SLC38A7, QPCT, SLC18A3	PTH1R 519/4885IL23R 905/4885KEAP1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.